Markets
Chicago Cubs v San Francisco Giants
Charles Liang, CEO of Super Micro, throws out the ceremonial first pitch (Thearon W. Henderson/Getty Images)

Super Micro soars as blockbuster Q2 results restore faith in the AI server company

This positive reaction breaks a long streak in which death and taxes had been joined by “Super Micro falling any time the company delivers financials” as one of life’s certainties.

Super Micro Computer more than doubled its sales in Q2, and, perhaps more importantly, may have also doubled the trust that investors have in the company.

Shares are soaring in the wake of the AI server company’s quarterly report, with top- and bottom-line results exceeding estimates, as did guidance for the current quarter. Management also raised its full-year sales guidance to “at least” $40 billion, up from an outlook of $36 billion in November. 

The story that management had been telling for the better part of the past year about customers waiting to order Blackwell racks, and then encountering some struggles in attempting to produce and deliver them, suddenly starts to look a little more reasonable — and like a corner has been turned for the business.

“The company’s data center building block solutions (DCBBS) is gaining momentum across key customers,” wrote Needham & Co. analyst Quinn Bolton. “Notably, DCBBS accounted for 4% of profit in F1H26, and management expects it to increase to a double-digit % by calendar year-end 2026.”

This positive reaction breaks a long streak in which death and taxes had been joined by “Super Micro falling any time the company delivers financials” as one of life’s certainties.

Consider:

Super Micro has now proven it can get a lot of money in the door, but translating that to the bottom line will remain a challenge going forward.

“The Grace-Blackwell 300 GPU ramp-up is resulting in large-scale cluster-AI deals that can sustain quarterly deal activity of $10-$12 billion through the year,” wrote Bloomberg Intelligence senior technology analyst Woo Jin Ho. “Yet the company’s margin isn’t improving, and the EPS projection implies a sub-7% gross margin for 3Q and potentially the year.”

More Markets

See all Markets
markets

Broadcom soars on Google’s plans for up to $185 billion in capex this year

Google’s capex guidance is Broadcom’s earnings guidance.

The hyperscaler and search giant said its 2026 capex budget would be between $175 billion and $185 billion, 55% higher than Wall Street had anticipated.

Accordingly, shares of the custom chip specialist are soaring in after-hours trading.

Broadcom has enjoyed a halo effect from Google’s capex plans and the success of its Gemini 3 model (trained on TPUs the two companies codesigned) over the past year.

But the custom chip designer had tumbled after its most recent earnings report, with some analysts attributing the decline to the dearth of new customer announcements. But who needs new customers when your current ones are opening their wallets this much?!?

Accordingly, shares of the custom chip specialist are soaring in after-hours trading.

Broadcom has enjoyed a halo effect from Google’s capex plans and the success of its Gemini 3 model (trained on TPUs the two companies codesigned) over the past year.

But the custom chip designer had tumbled after its most recent earnings report, with some analysts attributing the decline to the dearth of new customer announcements. But who needs new customers when your current ones are opening their wallets this much?!?

(J. Edward Moreno/Sherwood News)

Novo and Lilly agree prices are falling — and disagree on what comes next

Novo Nordisk and Eli Lilly are cutting prices to reach more patients — with sharply different expectations about what that means for sales.

markets

Ozempic is no longer the most searched for GLP-1 in the US

Ozempic, the popular diabetes drug made by Novo Nordisk, used to be shorthand for an entire class of diabetes and weight-loss medications. Not anymore.

According to Google Trends data, as of January, more people in the US are searching for Eli Lilly’s weight-loss shot, Zepbound, than Ozempic. At the same time, interest in the word “Ozempic” now sits roughly on par with searches for “peptides,” a catchall term for a booming, loosely regulated category of experimental supplements.

The numbers hint at a cultural shift: Ozempic is no longer the only word people reach for when they think about weight-loss drugs. The market — and the vocabulary around it — is fragmenting.

This shift also reflected in sales numbers. For several quarters now, Lillys diabetes and weight-loss drugs have outsold Novos, and that gap is expected to widen this year.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.